AUS
NZ
UK
CA
USA
IND
Highlights
- MIN shares trade well below long-term average price-to-sales ratio
- RMD remains active in global sleep and respiratory care market
- One ASX 100 company among the two could offer sector-specific potential
In recent market movements, two ASX-listed stocks have come into the spotlight due to noticeable shifts in their share prices and valuation metrics: Mineral Resources (MIN) and ResMed CDI (RMD). Both companies operate in distinct sectors—resources and healthcare—and present different angles of interest for investors following the Australian equities space.
Mineral Resources (ASX:MIN): Mining Strength with Multifold Capabilities
Mineral Resources is a diversified player in Australia's mining sector, primarily focusing on lithium and iron ore operations across Western Australia. The company extends its footprint through its wholly-owned subsidiary, CSI Mining Services, which supports external mining projects with infrastructure development and operational expertise across multiple Australian territories.
A unique aspect of Mineral Resources is its in-house engineering and construction capabilities, providing the business with increased operational control and efficiency. These capabilities aim to create strategic advantages in both cost management and timely execution of large-scale projects.
As of early July 2025, the share price of MIN has dropped by around 29.2% since the start of the year. Despite this, the company’s revenue trend has shown consistent growth over the past three years. From a valuation perspective, its current price-to-sales (P/S) ratio stands at approximately 0.92x—well below its five-year average of 3.02x. This suggests a significant gap between its historical valuation and present trading levels, prompting a closer look at underlying fundamentals.
Importantly, Mineral Resources is a member of the ASX 100 companies, placing it among the top-tier firms on the Australian Securities Exchange by market capitalisation.
ResMed CDI (ASX:RMD): Healthcare Innovation on a Global Scale
ResMed is a global medical technology firm with a specialisation in sleep apnea solutions and respiratory care. Its product line is well known for cloud-connected CPAP devices and ventilation systems that support both acute and chronic care.
Operating across more than 140 countries, ResMed serves its global clientele through two key divisions—Sleep and Respiratory Care, and Software as a Service (SaaS). Its SaaS arm offers digital solutions tailored for durable medical equipment providers, which play an essential role in enabling out-of-hospital care management.
Currently, ResMed shares are trading at a P/S ratio of 5.37x, lower than its long-term average of 8.70x. While the share price has recovered nearly 39.6% from its 52-week lows, the valuation metrics indicate potential room for further reassessment depending on future growth trends in healthcare technology.